Featured Research

from universities, journals, and other organizations

New guideline recommends caution regarding erythropoiesis-stimulating agents (ESA) use in cancer patients

Date:
October 26, 2010
Source:
American Society of Hematology
Summary:
An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia. While the guideline cautions that ESAs are associated with shorter survival and increased risk of thromboembolism -- blood clots -- and tumor progression, it also recognizes their major benefit of reducing the need for red blood cell transfusions, which can potentially cause serious infections and adverse reactions in the immune system.

Related Articles


"This updated guideline offers clinicians the latest synthesis of the medical evidence surrounding use of ESAs in patients with cancer, including appropriate cautions where evidence is lacking or where risks may outweigh the use of ESAs," said J. Douglas Rizzo, MD, MS, Co-Chair of the guideline panel and Professor of Medicine at the Medical College of Wisconsin.

Those risks may include thromboembolism or even death, according to new data cited in the guideline, which suggests that physicians avoid the use of ESAs in cancer patients who are not receiving chemotherapy, except for those with myelodysplastic syndrome (MDS). At the same time, the guideline confirms the effectiveness of ESAs in sparing patients the need for transfusions, which can substantially impact quality of life. By recommending that physicians discuss individual risks and benefits of ESAs and blood transfusion with patients prior to therapy, the guideline recognizes the critical role of shared decision-making between the patient and the physician.

In addition to outlining the clotting risks of ESAs, the guideline makes specific recommendations on usage and provides insights into disease progression and patient survival. The guideline also details new thresholds for initiation and modification of ESAs, which are consistent with current FDA labeling.

Originally published in 2002 and last updated in 2007, the guideline was derived from analysis of individual patient data, various medical literature, and systematic reviews of published clinical trials. In developing the update, panel members considered all relevant literature published between January 2007 and January 2010. Additional evidence was considered when it was considered pertinent to each section of the updated guideline.

"These guidelines touch on almost all aspects of the use of ESAs in patients with cancer and MDS, as well as secondary issues, such as the role of iron supplementation," said Samuel Silver, MD, a member of ASH's Committee on Practice and Professor of Internal Medicine at the University of Michigan. "These are issues that confront practicing hematologists and oncologists on a daily basis, and we hope that these evidence-based recommendations will influence practice standards and result in better care for patients."

The guideline will be published ahead of print on the websites of Blood (bloodjournal.org), ASH's scientific journal, and ASCO's Journal of Clinical Oncology (jco.org) at 4:00 p.m. on October 25. The guideline will be published in print in Blood on November 18 and in the Journal of Clinical Oncology on November 20.


Story Source:

The above story is based on materials provided by American Society of Hematology. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. D. Rizzo, M. Brouwers, P. Hurley, J. Seidenfeld, M. O. Arcasoy, J. L. Spivak, C. L. Bennett, J. Bohlius, D. Evanchuk, M. J. Goode, A. A. Jakubowski, D. H. Regan, M. R. Somerfield. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 2010; DOI: 10.1182/blood-2010-08-300541

Cite This Page:

American Society of Hematology. "New guideline recommends caution regarding erythropoiesis-stimulating agents (ESA) use in cancer patients." ScienceDaily. ScienceDaily, 26 October 2010. <www.sciencedaily.com/releases/2010/10/101026091601.htm>.
American Society of Hematology. (2010, October 26). New guideline recommends caution regarding erythropoiesis-stimulating agents (ESA) use in cancer patients. ScienceDaily. Retrieved April 19, 2015 from www.sciencedaily.com/releases/2010/10/101026091601.htm
American Society of Hematology. "New guideline recommends caution regarding erythropoiesis-stimulating agents (ESA) use in cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/10/101026091601.htm (accessed April 19, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, April 19, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Teen E-Cigarette Use Triples, Government Debates Regulations

Teen E-Cigarette Use Triples, Government Debates Regulations

Newsy (Apr. 19, 2015) The Centers for Disease Control and Prevention says in 2014, 13.4 percent of high school students reported smoking an e-cigarette within 30 days. Video provided by Newsy
Powered by NewsLook.com
India's Bidi Workers Suffer for 1,000-a-Day Habit

India's Bidi Workers Suffer for 1,000-a-Day Habit

AFP (Apr. 19, 2015) Popular because of their cheap price, bidis are the main source of income for millions of women and children who manufacture these Indian traditional cigarettes for roughly a dollar a day in dire conditions. Duration: 02:26 Video provided by AFP
Powered by NewsLook.com
Elmo Teams Up With Surgeon General To Promote Vaccinations

Elmo Teams Up With Surgeon General To Promote Vaccinations

Newsy (Apr. 18, 2015) Surgeon General Vivek Murthy released a video with Elmo to promote vaccinations. The video was released the same day the measles outbreak ended. Video provided by Newsy
Powered by NewsLook.com
Our Love Of Puppy Dog Eyes Explained By Science

Our Love Of Puppy Dog Eyes Explained By Science

Newsy (Apr. 17, 2015) Researchers found a spike in oxytocin occurs in both humans and dogs when they gaze into each other&apos;s eyes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins